To compare the efficacy and toxicity of naltrexone and placebo in the treatment of alcohol dependence. MEDLINE and EMBASE (both from 1976 to January 2001), PsycLIT and the Cochrane Controlled Trials Register were searched for publications in the English language. The search terms were: 'naltrexone' (exploded); 'randomized controlled trial' or 'random allocation' or 'all random'; 'human'; and 'alcohol'. The bibliographies of relevant articles were examined for additional studies. In addition, the manufacturer of naltrexone was asked for any additional complete RCTs, and key investigators in the field were contacted. Studies reported only as conference proceedings were excluded. Where multiple reports of the same study were identified, the report providing the greatest detail was included.
Naltrexone was significantly more effective in preventing relapse into heavy drinking than placebo. Using a randomeffects model, the RD was -14% (95% CI: -23, -5) and the pooled RR was 0.72 (95% CI: 0.55, 0.94). Significant heterogeneity was detected (chi-squared 11.9, d.f.=6, p=0.06) Abstinence.
Naltrexone was associated with significantly higher abstinence rates than placebo. Using the fixed-effect model, the RD was 10% (95% CI: 3.5, 16.3) and the pooled RR was 1.28 (95% CI: 1.08, 1.52). No significant heterogeneity was detected (chi-squared 9.7, d.f.=6, p=0.14).
Alcohol consumption outcomes.
Naltrexone-treated patients reported significantly fewer drinking days than placebo-treated patients. Using a fixedeffect model, the pooled WMD was -3% (95% CI: -5.4, -0.5). No significant heterogeneity was detected (chi-squared 5.75, d.f.=4, p=0.22). Naltrexone-treated patients reported significantly fewer drinks per drinking day per patient than placebo-treated patients. Using a fixed-effect model, the pooled WMD was -1.04% (95% CI: -2.0, -0.1). No significant heterogeneity was detected (chi-squared 2.97, d.f.=3, p=0.40).
Safety.
There was no statistically-significant difference between naltrexone and placebo in the number of patients reporting at least one adverse event (RD 1%, 95% CI: -6, 8) or the number of patients who discontinued the study due to an adverse event (RD 2%, 95% CI: -1, 5). No significant heterogeneity was detected for either outcome (p=0.30 and p=0.65, respectively).
Authors' conclusions
Naltrexone was more effective than placebo at reducing relapses to heavy drinking and at improving alcohol abstinence in the short-term. However, these conclusions were drawn from data collected over a 12-week period of treatment. The optimal duration of treatment cannot be determined.
CRD commentary
The aims were stated and the inclusion criteria were defined in terms of the study design, intervention, participants and outcome. Several relevant sources of literature were searched and attempts were made to locate unpublished material. By restricting eligible studies to those published in the English language, other relevant articles might have been omitted. Duplicate articles were removed but the methods used to select the studies were not described. Eligible studies were restricted to RCTs, and a formal validity assessment was undertaken using defined criteria. Only one reviewer assessed validity and extracted the data. Relevant data and the validity scores of individual studies were tabulated.
Statistical heterogeneity was assessed and reported. The differences between the individual studies in terms of the characteristics of the populations and the definitions of the outcomes, were described. The data were combined in a meta-analysis using both a fixed-effect and random-effects model. Despite evidence of statistical heterogeneity for the primary outcome of 'relapse rate', the authors incorrectly supported the use of a random-effects model and did not investigate potential causes of this heterogeneity. Without an exploration of the potential causes of heterogeneity among the studies with respect to relapse rates, it is not possible to determine the circumstances in which naltrexone is of benefit.
Implications of the review for practice and research
Practice: The authors state that additional research is required before recommendations can be made.
Research: The authors state that additional follow-up studies with suitable comparison groups and longer-term outcome results are necessary to examine the long-term efficacy and tolerability of naltrexone, particularly with respect to any influence on the rates of alcohol-related complications.
